Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Daniel C. Md Adelman sold 9,933 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $40.00, for a total value of $397,320.00. Following the transaction, the insider now owns 26,784 shares of the company’s stock, valued at approximately $1,071,360. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Aimmune Therapeutics, Inc. (AIMT) opened at $37.83 on Thursday. The firm has a market capitalization of $1,931.29, a price-to-earnings ratio of -16.10 and a beta of -0.66. Aimmune Therapeutics, Inc. has a 12 month low of $15.97 and a 12 month high of $40.65.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.09. sell-side analysts predict that Aimmune Therapeutics, Inc. will post -2.51 earnings per share for the current year.
A number of research analysts recently issued reports on AIMT shares. Credit Suisse Group boosted their price objective on Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. Zacks Investment Research lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Roth Capital assumed coverage on Aimmune Therapeutics in a research note on Monday, November 20th. They set a “buy” rating and a $60.00 target price on the stock. Piper Jaffray Companies lifted their target price on Aimmune Therapeutics from $38.00 to $60.00 and gave the company an “overweight” rating in a research note on Tuesday, December 5th. Finally, Wedbush reaffirmed an “outperform” rating and set a $70.00 target price (up previously from $42.00) on shares of Aimmune Therapeutics in a research note on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $55.43.
TRADEMARK VIOLATION NOTICE: “Daniel C. Md Adelman Sells 9,933 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock” was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://weekherald.com/2018/01/18/daniel-c-md-adelman-sells-9933-shares-of-aimmune-therapeutics-inc-aimt-stock.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.